{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:05:59Z","timestamp":1762160759688,"version":"3.37.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.expneurol.2009.07.011","type":"journal-article","created":{"date-parts":[[2009,7,19]],"date-time":"2009-07-19T08:09:45Z","timestamp":1247990985000},"page":"533-542","source":"Crossref","is-referenced-by-count":46,"title":["Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction"],"prefix":"10.1016","volume":"219","author":[{"given":"K.A.","family":"Stockwell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tayarani-Binazir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Iravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.W.","family":"Olanow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2009.07.011_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2009.07.011_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/mds.870090204","article-title":"N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease","volume":"9","author":"Belluzzi","year":"1994","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2004.11.013","article-title":"Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates","volume":"192","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib4","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3565(25)24503-7","article-title":"Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys","volume":"272","author":"Blanchet","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.07.011_bib5","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.20612","article-title":"Nondopaminergic mechanisms in levodopa-induced dyskinesia","volume":"20","author":"Brotchie","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.65","article-title":"Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover","volume":"49","author":"de la Fuente-Fernandez","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0022-3565(25)38236-4","article-title":"Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys","volume":"265","author":"Domino","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.07.011_bib8","first-page":"A293","article-title":"Stable rotigotine plasma concentrations over 24 hours in patients with early-stage Parkinson's disease after once-daily transdermal administration of rotigotine (Neupro)","volume":"66","author":"Elshoff","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2009.07.011_bib9","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/mds.20936","article-title":"Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure","volume":"21","author":"Fox","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/mds.870100108","article-title":"Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance","volume":"10","author":"Gancher","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0376-8716(94)01066-T","article-title":"The tonic\/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function","volume":"37","author":"Grace","year":"1995","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.expneurol.2009.07.011_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of l-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\\ increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2009.07.011_bib14","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.expneurol.2006.10.005","article-title":"Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets","volume":"204","author":"Jackson","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib15","first-page":"S90","article-title":"Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates","volume":"47","author":"Jenner","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev., Neurosci."},{"key":"10.1016\/j.expneurol.2009.07.011_bib17","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00702-007-0719-3","article-title":"Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation","volume":"114","author":"Kehr","year":"2007","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2009.07.011_bib18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbr.2008.06.021","article-title":"Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism","volume":"194","author":"Larramendy","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2009.07.011_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00702-007-0852-z","article-title":"Pharmacological treatment of Parkinson's disease: life beyond dopamine D2\/D3 receptors?","volume":"115","author":"Linazasoro","year":"2008","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2009.07.011_bib20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0014-2999(89)90348-8","article-title":"Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437","volume":"166","author":"L\u00f6schmann","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib21","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","article-title":"Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous l-DOPA: studies in intact and 6-hydroxydopamine-treated rats","volume":"72","author":"Miller","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2009.07.011_bib22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1586\/14737175.6.9.1275","article-title":"Rotigotine for the treatment of Parkinson's disease","volume":"6","author":"Morgan","year":"2006","journal-title":"Expert Rev. Neurotherapeutics"},{"key":"10.1016\/j.expneurol.2009.07.011_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WNF.0b013e3180ed449f","article-title":"Enteral levodopa\/carbidopa infusion in advanced Parkinson disease: long-term exposure","volume":"31","author":"Nyholm","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib24","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2009.07.011_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002826-200001000-00007","article-title":"A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study. Parkinson Study Group","volume":"23","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/mds.1143","article-title":"Idazoxan, an alpha-2 antagonist, and l-DOPA-induced dyskinesias in patients with Parkinson's disease","volume":"16","author":"Rascol","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib28","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/mds.20988","article-title":"Development of dyskinesias in a 5-year trial of ropinirole and l-dopa","volume":"21","author":"Rascol","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/FBP.0b013e3280ebb400","article-title":"Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates","volume":"18","author":"Rose","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mds.10464","article-title":"Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"18","author":"Savola","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejphar.2008.01.038","article-title":"Continuous stimulation of dopaminergic receptors by rotigotine does not interfere with the sleep\u2013wake cycle in the rat","volume":"584","author":"Scheller","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2008","journal-title":"Naunyn-Schmiedebergs Arch. Pharmacol"},{"key":"10.1016\/j.expneurol.2009.07.011_bib34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00702-008-0102-z","article-title":"Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements","volume":"115","author":"Schmidt","year":"2008","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.expneurol.2009.07.011_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/mds.870110203","article-title":"An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets","volume":"11","author":"Smith","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib36","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mds.10394","article-title":"Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure","volume":"18","author":"Smith","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2009.07.011_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/01.WNF.0000220818.71231.DF","article-title":"Switching from levodopa to the long-acting dopamine D2\/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates","volume":"29","author":"Smith","year":"2006","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib38","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/brain\/awf214","article-title":"Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease","volume":"125","author":"Stocchi","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2009.07.011_bib39","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archneur.62.6.905","article-title":"Intermittent vs. continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study","volume":"62","author":"Stocchi","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2008.01.019","article-title":"Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets","volume":"211","author":"Stockwell","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib41","first-page":"613","article-title":"Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats","volume":"47","author":"Swart","year":"1992","journal-title":"Pharmazie"},{"issue":"Pt 1B","key":"10.1016\/j.expneurol.2009.07.011_bib42","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/brain\/114.1.601","article-title":"Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients","volume":"114","author":"Vaamonde","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2009.07.011_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-2999(88)90783-2","article-title":"N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models","volume":"147","author":"Van der Weide","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2009.07.011_bib44","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jps.2600830533","article-title":"Pharmacokinetic study of (S)-(-)-2-(N-propyl-N-(2-thienylethyl)amino)-5-hydroxytetralin infusion in cynomolgus monkeys","volume":"83","author":"Walters","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.expneurol.2009.07.011_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1358\/dot.2006.42.1.932510","article-title":"Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease","volume":"42","author":"Zareba","year":"2006","journal-title":"Drugs Today (Barc.)"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488609002787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488609002787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T04:50:26Z","timestamp":1739249426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488609002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0014488609002787"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2009.07.011","relation":{},"ISSN":["0014-4886"],"issn-type":[{"type":"print","value":"0014-4886"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}